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PAPER
Connecting impairment, disability, and handicap in
immune mediated polyneuropathies
I S J Merkies, P I M Schmitz, F G A van der Meché, J P A Samijn, P A van Doorn, for the
Inflammatory Neuropathy Cause and Treatment (INCAT) group
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Background: In the World Health Organisation (WHO) International Classification of Impairments,
Disabilities, and Handicaps (ICIDH), it is suggested that various levels of outcome are associated with
one another. However, the ICIDH has been criticised on the grounds that it only represents a general,
non-specific relation between its entities.
Objective: To examine the significance of the ICIDH in immune mediated polyneuropathies.
Methods: Four impairment measures (fatigue severity scale, MRC sum score, “INCAT” sensory sum
score, grip strength with the Vigorimeter), five disability scales (nine hole peg test, 10 metres walking
test, an overall disability sum score (ODSS), Hughes functional grading scale, Rankin scale), and a
handicap scale (Rotterdam nine items handicap scale (RIHS9)) were assessed in 113 clinically stable
patients (83 with Guillain–Barré syndrome, 22 with chronic inflammatory demyelinating polyneuropa-
thy, eight with a gammopathy related polyneuropathy). Regression analyses with backward and
forward stepwise strategies were undertaken to determine the correlation between the various levels of
outcome (impairment on disability, impairment on handicap, disability leading to handicap, and
impairment plus disability on handicap).
Results: Impairment measures explained a substantial part of disability (R2 = 0.64) and about half of
the variance in handicap (R2 = 0.52). Disability measures showed a stronger association with handi-
cap (R2 = 0.76). Combining impairment and disability scales accounted for 77% of the variance in
handicap (RIHS9) scores.
Conclusions: In contrast to some suggestions, support for the ICIDH model is found in the current study
because significant associations were shown between its various levels in patients with immune medi-
ated polyneuropathies. Further studies are required to examine other possible contributors to deficits in
daily life and social functioning in these conditions.
In 1980, The World Health Organisation (WHO) publishedthe International Classification of Impairments, Disabilities, andHandicaps (ICIDH), staging the consequences of an under-
lying pathology.1 In this model, an association was suggested
between the various dimensions. The ICIDH levels are defined
as follows: impairment represents the direct physiological con-
sequences of the underlying pathology (thus it represents a
disturbance at the organ level); disability reflects the conse-
quences of impairment in terms of functional performance
and activity; handicap is described as a disadvantage for a given
individual resulting from an impairment or disability that
limits or prevents the fulfilment of a role that is normal.1 Col-
lectively, the different levels are referred to as “disablement.”
Impairment and disability measures are logical targets for
physicians in assessing outcomes in general medicine.
However, measurements of handicap should be made more
often, particularly in patients with chronic conditions or
diseases that have a long term impact on life, because handi-
cap represents the end stage of a common disablement
pathway.1 2 Despite the conceptual advance of the ICIDH
model, the concept has been criticised. In particular, it has
been argued that the suggested association between the vari-
ous levels represents only a general non-specific relation.3 4 A
disappointing association between various ICIDH levels has
also been demonstrated in cardiopulmonary conditions.5 6
Our aim in this study was to evaluate the possible linkage
between impairment, disability, and handicap in patients with
sensory-motor immune mediated polyneuropathies, using a
set of scales that cover the most important symptoms and
signs in these conditions. The ultimate goal was to determine
the proportion of handicap variance explained by the
combined impairment and disability measures. We believed
that these evaluations would increase our knowledge of how
these conditions influence life in the long term. Also, the
strength of the relations between items representing the vari-
ous levels of outcome would help physicians to use them as a
proxy for measuring other levels of clinical deficit. For exam-
ple, grip strength (an impairment measure) could be an indi-
rect indicator of arm disability, because it shows a moderate to
good association with an arm disability scale.7
METHODS
Patients
We recruited 113 clinically stable patients (83 with Guillain–
Barré syndrome, 22 with chronic inflammatory demyelinating
polyneuropathy, eight with a gammopathy related polyneu-
ropathy) from the Rotterdam immune mediated polyneuropa-
thy databank and the Dutch Guillain–Barré syndrome study
group (stable group). Patients with these three conditions
were recruited as it is argued that they represent parts of a
continuum with respect to their pattern of neuromuscular
dysfunction.8 The selected patients still had residual symp-
toms or signs of their illness, representing a broad range of
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disability. Nine patients with chronic inflammatory demyeli-
nating polyneuropathy required interval treatment with
intravenous immunoglobulin over periods ranging from
weeks to months. With this treatment their clinical condition
has been stable for more than six months. Six patients with
gammopathy related polyneuropathy (three with IgG type,
two with IgM type, and one with IgG+IgM type) had an asso-
ciated demyelinating polyneuropathy with minor concurrent
axonal damage in three. An axonal polyneuropathy was diag-
nosed in the remaining two patients with gammopathy
related polyneuropathy (one IgA type and one IgG type). All
patients with Guillain–Barré syndrome and chronic inflam-
matory demyelinating polyneuropathy met the international
criteria for their illness.9 10 The diagnosis of gammopathy
related polyneuropathy was established after excluding all
possible causes for the gammopathy and polyneuropathy.11
Assessment tools/scales
Rationale for scale selection
Scales were selected by a panel of 13 expert neurologists, all
members of the Inflammatory Neuropathy Cause and
Treatment Group (INCAT)—a collaborating force of European
neurologists with a special interest in neuroimmunological
illnesses. Selection was based on their experience, taking into
account the clinical spectrum of sensory-motor immune
mediated polyneuropathies.8 Because the motor and sensory
systems are primarily affected in these conditions, the MRC
sum score and a new sensory sum score were selected to
examine the deficits.12 13 As distal weakness could predomi-
nate, grip strength was used to measure “focal impairment” of
the hand.7 A fatigue scale was also selected, as fatigue has
been found to be a major complaint in patients with immune
mediated polyneuropathies.14 15 Various scales were selected to
measure different aspects of disability.4 12 16–19 An overall
disability scale (measuring arm and leg function) was chosen
as the final disability target for the regression studies, based
on its comprehensive nature compared with the other disabil-
ity measures.12 16–19 Finally, a handicap measure that has been
subjected to psychometric evaluation in immune mediated
polyneuropathies was chosen to complete the set of scales.20
Description of the scales
The MRC sum score is a summation of the Medical Research
Council grades (range 0–5) for the following muscle pairs:
upper arm abductors, elbow flexors, wrist extensors, hip flex-
ors, knee extensors, and foot dorsal flexors. The MRC sum
score ranges from 0 (“total paralysis”) to 60 (“normal
strength”).12 The subdivisions MRC-arms (range 0–30) and
MRC-legs (range 0–30) were also incorporated separately in the
univariate regression analyses.
The INCAT sensory sum score (ISS) has recently been
evaluated in patients with immune mediated
polyneuropathies.13 In brief, this scale comprises pin prick and
vibration sense plus a two point discrimination test in the
arms and legs, and ranges from 0 (“normal sensation”) to 20
(“most severe sensory deficit”).13 The sensory modes repre-
senting the ISS were also analysed separately in the univariate
regression analyses to determine their impact on disability
and handicap (pin prick, arm + leg: range 0 (no deficit) to 8
(maximum deficit); vibration, arm + leg: range 0 (no deficit)
to 8 (maximum deficit); two point discrimination: range 0 (no
deficit) to 4 (maximum deficit)).
The Vigorimeter (Martin, Tuttlingen, Germany) is a hand
held dynamometer used to measure grip strength.7 A medium
sized bulb was used in the patients selected. The pressure in
the bulb is registered on a manometer and expressed in kilo-
pascals (kPa; range 0–160).7
The Dutch version of the fatigue severity scale (FSS) was used
to assess fatigue.14 15 The FSS is a brief and simple self assessed
questionnaire containing nine items with answers ranging
from 1 (“strongly disagree”) to 7 (“strongly agree”) for each
inquiry. The mean score of the nine inquiries ranges from 1
(“no signs of fatigue”) to 7 (“most disabling fatigue”).14 15
The overall disability sum score (ODSS) is derived from a recent
arm and leg disability scale, with a total score ranging from 0
(“no sign of disability”) to 12 (“most severe disability”).16 The
ODSS comprises a good functional description of the arms
and legs in checklist form suitable for interviewing patients.
Daily arm activities such as dressing the upper part of the
body, doing up and undoing buttons and zips, washing and
brushing the hair, using a knife and fork, and turning a key in
a lock are investigated. Problems with walking are also evalu-
ated taking into account the use of a walking aid.16 The ODSS,
its arm disability scale, and its leg disability scale were exam-
ined separately in the univariate regression analyses to deter-
mine their association with the handicap level.
ThemodifiedHughes functional grading scale (f score) assesses
functional ability, particularly mobility, and ranges from 0 (no
symptoms or signs) to 5 (requiring artificial ventilation for at
least part of the day).12
The Rankin scale has primarily been used in patients with
stroke.17 The grades of this scale range from 0 (no symptoms at
all) to 5 (severe disability, bedridden, incontinent, and requir-
ing constant nursing care and attention).17
The nine hole peg test and the 10 metres walking test were also
used in all patients to measure “focal disability.”4 18 19
The recently constructed Rotterdam nine items handicap scale
(RIHS9) has been evaluated in immune mediated
polyneuropathies.20 The RIHS9 comprises nine inquiries
(mobility indoors, mobility outdoors, kitchen tasks, domestic
tasks indoors, domestic tasks outdoors, leisure activities
indoors, leisure activities outdoors, ability to drive a car/go by
bus/ride a bicycle, and ability to work/study),with a total score
ranging from 9 (“unable to fulfil any applicable task or activ-
ity”) to 36 (“able to fulfil all applicable tasks and
activities”).20
Test procedures
General aspects
All participants gave their informed consent before the study.
All procedures were done in a quiet and comfortably warm
room at our outpatient clinic. The assessments were under-
taken in random order. All participants received instructions
on how to fill in the FSS form.
For the assessment of strength, the joint and limb position
was standardised for each muscle group before the start of the
study, as was the point at which counterforce was applied.
Sensory modes were examined in triplicate under standard
conditions15 with the patients lying in the supine position.
Grip strength with the Vigorimeter was assessed according
to the recommendations of the American Society of Hand
Therapists.21 Three grip strength measurements with maxi-
mum voluntary contractions for each hand were taken in
alternating order. Between each trial there was a pause of 30
seconds. The results of three trials for each hand were
averaged and considered to represent the grip strength score
for that hand.
All patients received training in assessing the nine hole peg
test before the start of the study, to exclude any training effect.
The patients were asked—under the prescribed standard con-
ditions in alternating order for both hands—to pick up nine
pegs from a tray at table height and place them as quickly as
possible into nine holes in a neighbouring horizontal board.
After this procedure, the pegs then had to be removed as fast
as possible.4 18 Patients were also requested to walk 10 metres
in a straight line at their prefered speed, using whatever aid
was needed.4 19
Three measures were completed for each of these tests and
the corresponding time was recorded at each assessment (in
seconds). For each test separately, the mean time of
completion was calculated by averaging the three measures
obtained.
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Validity and reliability
The minimum entry requirement for regression model analy-
ses was that a scale had been shown to be valid and reliable.
These criteria had already been fulfilled for the MRC sum
score, ISS, grip strength with the Vigorimeter, FSS, f score,
ODSS, and RIHS9.7 12 13 15 16 20 The remaining scales (Rankin
scale, nine hole peg test, and 10 metres walking test) were
declared valid by the panel of experts.
For the assessment of the validity and reliability of the
scales, two neurologists and six experienced residents in neu-
rology formed 28 different couples. Preceding the study, all
investigators received instructions in assessing the outcome
measures. Twenty seven (“variable”) couples investigated a
total of 68 patients (two to three patients for each couple). The
remaining 45 stable patients were investigated by the “experi-
enced” couple (IM + JS). The latter couple was formed to
examine the effect of training (and thus a possible increase in
reliability) when using the scales often. The patients were
examined on two different occasions at our outpatient clinic.
During the first visit the two members of an appointed pair
arrived at their scores independently and consecutively (usu-
ally within two hours) (interobserver variability). Within two
to four weeks, the patient returned for a second visit and only
one investigator of the earlier assigned pair examined the
patient again (intraobserver variability) without having access
to the previous results. The assessment sequence at entry and
the examination at the second visit were equally distributed
among the members of an assigned couple. Eventually, each
member of a couple examined approximately the same
number of patients.With the exception of the f score, all scales
were assessed at each visit in all patients. For the validity and
regression model studies, only the scale values obtained at
entry were used. The study took place between December 1998
and January 2000 and was performed on behalf of the INCAT
group.
Statistics
Validity and reliability of scales not thoroughly evaluated
in immune mediated polyneuropathies
The correlation between the Rankin scale, the nine hole peg
test, and the 10 metres walking test was analysed using the
Spearman rank correlation test. Inter-rater and intrarater reli-
ability was quantified by estimation of the intraclass correla-
tion coefficient using a one way random effects analysis of
variance model for the two investigator (“experienced” and
“variable”) groups.
Regression model studies
Univariate and multivariate linear regression analyses were
done to determine the association between impairment,
disability, and handicap outcome measures. The ODSS was
used as the disability dependent variable in the studies
analysing the association with impairment measures (ex-
planatory variables). The ODSS was chosen because of its
comprehensiveness in monitoring disability compared with
the f score and Rankin scale.16 The latter two scales assess dis-
ability with a strong emphasis on mobility and do not provide
information on the arms. The RIHS9 was the dependent vari-
able for the analyses of impairment and disability measures
leading to handicap.20 If necessary, a transformation of the
various scales was done to obtain a normal distribution
Table 1 Basic characteristics of stable patients with
immune mediated polyneuropathies
Demographic variables and tests
Number of patients 113
Guillain–Barré syndrome (n) 83
CIDP (n) 22
MGUSP (n) 8
Age at entry (years) 54.3 (15.1), 14 to 84
Duration of symptoms to onset of study
(years)
6.9 (3.1), 0.5 to 28
Sex distribution (n (%))
Male 59 (52)
Female 54 (48)
Fatigue severity scale score at entry 5.6 (1.4), 1 to 7
MRC sum score at entry 53.3 (7.7), 16 to 60
INCAT sensory sum score at entry 4.4 (4.1), 0 to 15
Grip strength values with the Vigorimeter
at entry (kPa)
Right hand 66.9 (33.6), 0 to 156
Left hand 64.9 (32.9), 0 to 158
Overall disability sum score at entry 3.5 (2.2), 0 to 11
f Score at entry 1.8 (0.9), 1 to 4
Rankin score at entry 2.1 (0.9), 0 to 4
Nine hole peg test at entry (s)*
Right hand 31 (20), 15 to 135
Left hand 33 (25), 16 to 192
Ten metre walking test at entry (s)† 10.4 (5.8), 5 to 32
Rotterdam nine item handicap scale at
entry
29.5 (6), 14 to 36
Values are mean (SD) and range unless stated otherwise.
*Five patients could not fulfil the nine hole peg test.
†Seven patients were unable to walk.
CIDP, chronic inflammatory demyelinating polyneuropathy; INCAT,
inflammatory neuropathy cause and treatment group; MGUSP,
polyneuropathy associated with a monoclonal gammopathy of
undetermined significance; MRC, Medical Research Council.
Table 2 Validity of the selected scales in 113 patients with immune mediated
polyneuropathies
Rankin 9HPT-RH 9HPT-LH 10MWT
“Experienced” examiners (couple No 1); n=45 (Spearman’s rank correlation coefficient)
Rankin –
9HPT-RH 0.52* –
9HPT-LH 0.56** – –
10MWT 0.51* 0.50* 0.49* –
“Variable” examiners (couples Nos 2–28); n=68 (Spearman’s rank correlation coefficient)
Rankin –
9HPT-RH 0.44* –
9HPT-LH 0.42* – –
10MWT 0.65** 0.66** 0.61** –
The validity and reliability have already been established for the MRC sum score, “INCAT” sensory sum
score, grip strength by Vigorimeter, fatigue severity scale, Hughes’ functional grading scale (f score), and the
Rotterdam nine item handicap scale.7 12 13 15 20 The validity and reliability values of the remaining scales are
presented in this table.
*p < 0.001; **p < 0.0001.
9HPT-LH, nine hole peg test, left hand; 9HPT-RH, nine hole peg test, right hand; 10MWT, 10 metres walking
test; RIHS9, Rotterdam nine item handicap scale.
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pattern. The other scales showed a Gaussian distribution pat-
tern. Univariate regression studies were performed first, aim-
ing for the best fit between the dependent and independent
variable through a systematic evaluation of graphs showing
the linear regressions, including a restricted cubic spline func-
tion on the independent variable.22 Subsequently, multivariate
linear regressions were carried out for the various linkages
(disability on impairment, handicap on impairment, handicap
on disability, and handicap on impairment plus disability),
using stepwise backward eliminating, forward adding
strategies. The strength of the association between the
dependent variable and the explanatory variables was
presented as R2: the fraction of the variance explained by the
independent variables from the regression model.
In the multivariate regression models, only the right hand
grip strength and nine hole peg values are presented, because
the regressions for the right hand and the left hand values
were similar.
All analyses were done using Stata 6.0 for Windows 98
(Stata Statistical Software, release 6.0; Stata Corporation,
Texas, USA). A probability (p) value of < 0.05 was considered
statistically significant.
RESULTS
General aspects
The group of patients (54 female and 59 male) had a mean
duration of symptoms up to the time of the study of 6.9 years.
Seven were bed bound and 14 required assistance or a device
to walk short distances. The remaining 92 patients could walk
without support. The values for all the scales in these patients
are listed in table 1.
Validity and reliability
Validity and reliability have already been demonstrated for the
MRC sum score, ISS, Vigorimeter, FSS, f score, ODSS, and
RIHS9. The correlation studies between the remaining scales
are presented in table 2. In general, moderate to good correla-
tions were obtained for each scale, thus demonstrating their
validity. Significant reliability values were also found for these
scales (table 3). Hence the basic requirements were fulfilled
for these outcome measures, enabling their participation in
the regression studies.
Univariate regression studies of impairment leading to
disability
The univariate regression studies are presented in table 4. The
MRC sum score and grip strength values were the strongest
explanatory variables of disability, each accounting for
40–45% of the variance in ODSS scores. The MRC score for the
legs had a higher impact than the score for the arms (table 4).
The strongest explanatory sensory mode was the two point
discrimination test (table 4). Fatigue had a non-significant
impact on disability.
Table 3 Reliability of selected scales in patients with immune-mediated
polyneuropathies (n=113)
“Experienced” couple of examiners
(couple No 1; 45 patients)*
“Variable” couples of examiners
(couples Nos 2–28; 68 patients)*
Interobserver
agreement
Intraobserver
agreement
Interobserver
agreement
Intraobserver
agreement
Rankin scale 0.77 0.89 0.70 0.85
Nine hole peg test
Right hand 0.93 0.95 0.96 0.90
Left hand 0.93 0.89 0.97 0.94
10 metre walk test 0.99 0.85 0.93 0.96
*Intraclass correlation coefficient (R) (p < 0.0001 for all associations).
Table 4 Univariate regression studies showing the association between impairment, disability, and handicap outcome
measures in immune mediated polyneuropathies (n = 113)
Explanatory variable
Dependent variable
Overall disability sum score Rotterdam 9 item handicap scale
R2 p Value R2 p Value
Fatigue severity scale 0.03 0.4 0.05 0.1
MRC sum score 0.45 <0.0001 0.35 <0.0001
MRC-arms 0.37 <0.0001 0.24 <0.0001
MRC-legs 0.43 <0.0001 0.35 <0.0001
INCAT sensory sum score 0.21 <0.0001 0.16 0.0003
Pin prick arm+leg 0.14 0.0003 0.11 0.002
Vibration arm+leg 0.10 0.002 0.10 0.004
2 point discrimination 0.19 <0.0001 0.11 0.002
Grip strength
Right hand 0.40 <0.0001 0.31 <0.0001
Left hand 0.43 <0.0001 0.39 <0.0001
Functional grading scale – – 0.59 <0.0001
Overall disability sum score – – 0.65 <0.0001
Arm disability scale – – 0.47 <0.0001
Leg disability scale – – 0.52 <0.0001
Nine hole peg test
Right hand – – 0.33 <0.0001
Left hand – – 0.40 <0.0001
Ten metre walk test – – 0.53 <0.0001
Rankin scale – – 0.63 <0.0001
INCAT, inflammatory neuropathy cause and treatment group; MRC, Medical Research Council.
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Univariate regression studies of impairment leading to
handicap
Approximately one third of the handicap was explained by the
MRC sum score and grip strength, separately. A lower but still
significant association was obtained between the ISS and
RIHS9 values (R2 = 0.16). Again, fatigue did not have a
significant impact on handicap (table 4).
Univariate regression studies of disability leading to
handicap
The overall disability sum score was the strongest explanatory
variable of handicap, accounting for 65% of the variance in
RIHS9 values. The functional grading scale and the Rankin
scale were also both highly associated with handicap. The nine
hole peg test had the weakest association with the RIHS9 of all
disability measures (table 4).
Multivariate regression studies
In fig 1, the conceptual framework of the ICIDH is presented,
showing the proportions of the variances that were obtained
from multivariate regression studies between the various lev-
els of outcome in patients with immune mediated polyneu-
ropathies. As can be seen, approximately two thirds of the dis-
ability (assessed by the ODSS) was explained by impairment
measures (R2 = 0.64). Fatigue (FSS) was the only impairment
measure that did not contribute significantly to this model.
All impairment measures remained significantly associated
with handicap, accounting for a combined 52% of the variance
in RIHS9 values (fig 1). Disability measures explained 76% of
disturbances resulting from handicap. The Rankin scale and
ODSS were the strongest contributors to this model. The nine
hole peg test and the f score were eliminated.
Combining the impairment and disability measures ac-
counted for 77% of the variance in handicap scores. In this
model, the Rankin scale, the ODSS, the 10 metre walking test,
and fatigue (FSS) were the significant explanatory contribu-
tors. The values of sensation (ISS), dexterity (nine hole peg
test), general strength (MRC sum score), grip strength (Vigo-
rimeter), and functional grading scale (f score) were all
excluded, as their contribution was not significant.
Adding patient variables (age, sex, and duration of illness)
resulted in only a minor increase in the proportion of the vari-
ance explained (impairment to disability: R2 from 0.64 to 0.67;
impairment to handicap: R2 from 0.52 to 0.57; disability to
handicap: R2 from 0.76 to 0.79; impairment + disability lead-
ing to handicap: R2 from 0.77 to 0.80).
DISCUSSION
In this study, we found significant and meaningful associa-
tions between the levels of the ICIDH in patients with immune
mediated polyneuropathies using validated and reliable
outcome measures.1 23 These results are in contrast with some
reports that have suggested only a marginal non-specific
association between ICIDH levels of outcome.3–6 Harwood and
colleagues also demonstrated the applicability of the ICIDH
model in an outstanding paper addressing the associations
between its levels in elderly people.2
Our study provides further information on the extent to
which an impairment measure contributes to the assessment
of disability or handicap in comparison with other impair-
ment variables. Physicians could use this information to
choose a suitable scale acting as an outcome measure at a par-
ticular level and indirectly at another level, depending on the
strength of its association with other variables. However, the
minimum required strength of the association should be
established by determining the significance of the correlations
in the immune mediated polyneuropathies.
In the current study, only two thirds of the disability was
explained by the impairment measures we used. The MRC
sum score and grip strength (Vigorimeter) values were the
strongest explanatory variables, which is consistent with ear-
lier reports.24 25 Other explanatory variables should also be
considered, as the associations were not absolute. In a study of
patients with Guillain–Barré syndrome, psychological factors
were consistently found to contribute to disability in addition
to muscle weakness, sensory dysfunction, and fatigue.25
To our knowledge, our study is the first to analyse the
impact of impairments leading to handicap in the immune
mediated polyneuropathies. However, only half (52%) of the
variance in handicap was explained by impairment variables
(table 4), suggesting a major contribution from other factors.
The strongest association was obtained between the combined
impairment and disability measures explaining handicap.
Almost 80% of handicap variance was explained by these
measures, thus supporting the assumed associations given in
the ICIDH model.1 However, as the association was not abso-
lute, other explanatory factors should be considered as poten-
tial contributors to handicap. Such factors might be pain, psy-
chological influences such as anxiety, depression, coping
mechanism, motivation, social support, and physical condi-
tion in terms of endurance.25–29 The assessment and incorpora-
tion of these factors could be cardinal for further improve-
ments in our understanding of the associations and
consequences of immune mediated polyneuropathies at the
various levels of outcome. We should, however, bear in mind
that clinicians and other health workers (for example physical
therapists) strive as much as possible to reduce the strength of
the association between the various levels of outcome by pre-
scribing medication, giving advice, recommending the use of
certain aids, and creating a social support network. These
“remedies” are generally in addition to any treatment that
affects the impairment and disability directly. This is one of
Figure 1 Multivariate regression studies linking impairment, disability, and handicap in 113 patients with immune mediated
polyneuropathies.
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the main reasons why the WHO recently published its second
and more comprehensive edition of the ICIDH model for all
diseases and disorders, integrating personal and external
(social and environmental) factors as well.30
Some methodological issues in our study need to be
addressed. First, we must be aware that the rejection of an
outcome measure (predictor) in a stepwise multiple
regressionmodel does not happen only when a variable has no
relevance to the outcome, but also when other incorporated
variables in the model already supply most, if not all, the
information the rejected predictor contains. Second, the asso-
ciations obtained in the current study were directly linked to
the scales used and might vary if other outcome measures
were employed. Our choice of outcome measures was
determined by the views of experts in the field of neuroimmu-
nological disorders and by the established value of most of the
scales selected.
Conclusions
We have shown that the framework of the WHO International
Classification of Impairments, Disabilities, and Handicaps is applica-
ble to the immune mediated polyneuropathies. Further infor-
mation is provided on the consequences of these illnesses
which may lead to deficits at various levels of outcome.
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